{
    "nctId": "NCT02333890",
    "briefTitle": "A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer",
    "officialTitle": "A Phase 2 Randomized, Double-blind, Window of Opportunity Trial Evaluating Clinical and Correlative Effects of Chloroquine as a Novel Therapeutic Strategy in Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Invasive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Effect of a brief course of CQ on tumour proliferation and apoptosis",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* newly diagnosed histologically confirmed primary invasive breast cancer who is currently not undergoing any treatment while awaiting surgery in the next 2-6 weeks\n* tumour \u2265 1.5 cm by palpation or imaging\n* ECOG performance status 0-2\n* written informed consent for the study\n\nExclusion Criteria:\n\n* Known Metastatic breast cancer\n* history of pre-existing known retinal or ocular pathology patient has only one functioning eye\n* abnormal hepatic function (serum AST or ALT \\>3x upper limit of normal)\n* currently on CQ or HCQ or has been on the drug within the past 3 months for other conditions\n* known history of psoriasis\n* known history of epilepsy or seizures\n* electrocardiogram showing QT prolongation based on QTc interval \\>450 ms\n* inability to comply with a study protocol (abuse of alcohol, drugs or psychotic states)\n* current known pregnancy or actively nursing\n* allergic reactions to quinolones or CQ\n* inability to consent.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}